Invasive lobular carcinoma - Revision history

Mikael Häggström: /* Microscopic evaluation */ +Subtle

2024-02-06T15:07:12Z

Microscopic evaluation: +Subtle

← Older revision		Revision as of 11:07, 6 February 2024
Line 11:		Line 11:
	==Microscopic evaluation==		==Microscopic evaluation==
	[[File:Classic Invasive Lobular Carcinoma of the Breast (6813147194).jpg\|thumb\|Invasive lobular carcinoma.]]		[[File:Classic Invasive Lobular Carcinoma of the Breast (6813147194).jpg\|thumb\|Invasive lobular carcinoma.]]
			[[File:Histopathology of subtle invasive lobular carcinoma, annotated.png\|thumb\|ILC may be subtle on low magnification (left). Higher magnification (right) shows invasive growth pattern and vesicular nuclei with prominent nucleoli.]]
	===Characteristics===		===Characteristics===
	The "classic" pattern is round or ovoid cells with little cytoplasm in a single-file infiltrating pattern, sometimes concentrically giving a targetoid pattern.		The "classic" pattern is round or ovoid cells with little cytoplasm in a single-file infiltrating pattern, sometimes concentrically giving a targetoid pattern.

Mikael Häggström: Histopathology of invasive ductal carcinoma of the breast.jpg

2023-12-10T20:15:07Z

Histopathology of invasive ductal carcinoma of the breast.jpg

← Older revision		Revision as of 16:15, 10 December 2023
Line 56:		Line 56:
	*'''[[Invasive ductal carcinoma]]''' typically has duct-forming tumor cells rather than single files of tumor cells. In uncertain cases, stain for E-cadherin and p120:		*'''[[Invasive ductal carcinoma]]''' typically has duct-forming tumor cells rather than single files of tumor cells. In uncertain cases, stain for E-cadherin and p120:
	<gallery mode=packed heights=180>		<gallery mode=packed heights=180>
	File:~~Invasive~~ ductal carcinoma~~, with occasional entrapped normal ducts~~.jpg\|thumb\|'''[[Invasive ductal carcinoma]]''', with occasional entrapped normal ducts (arrow).		File:Histopathology of invasive ductal carcinoma of the breast.jpg\|thumb\|'''[[Invasive ductal carcinoma]]''', with occasional entrapped normal ducts (arrow).
	File:Chromogenic immunohistochemistry for E-cadherin in invasive lobular carcinoma, annotated.jpg\|'''E-cadherin''' is '''negative''' in invasive '''lobular''' carcinoma (shown), but has membranous staining in [[invasive ductal carcinoma]]		File:Chromogenic immunohistochemistry for E-cadherin in invasive lobular carcinoma, annotated.jpg\|'''E-cadherin''' is '''negative''' in invasive '''lobular''' carcinoma (shown), but has membranous staining in [[invasive ductal carcinoma]]
	File:Chromogenic immunohistochemistry for p120 in invasive lobular carcinoma.jpg\|'''p120''' has '''cytoplasmic''' staining in invasive lobular carcinoma (shown), but has membranous staining in [[invasive ductal carcinoma]]		File:Chromogenic immunohistochemistry for p120 in invasive lobular carcinoma.jpg\|'''p120''' has '''cytoplasmic''' staining in invasive lobular carcinoma (shown), but has membranous staining in [[invasive ductal carcinoma]]

Mikael Häggström: /* Overall grade */ Calcs

2023-12-08T19:26:33Z

Overall grade: Calcs

← Older revision		Revision as of 15:26, 8 December 2023
Line 86:		Line 86:
	* 6-7 '''Grade 2''' tumor ('''moderately differentiated'''). Medium prognosis.		* 6-7 '''Grade 2''' tumor ('''moderately differentiated'''). Medium prognosis.
	* 8-9 '''Grade 3''' tumor ('''poorly differentiated'''). Worst prognosis.		* 8-9 '''Grade 3''' tumor ('''poorly differentiated'''). Worst prognosis.
			{{Microcalcifications in breast cancer}}
			{{Immunohistochemistry evaluation of invasive breast cancer}}

	~~{{Immunohistochemistry evaluation of invasive breast cancer}}~~
	====Estrogen and progesterone receptors====		====Estrogen and progesterone receptors====
	{{Estrogen and progesterone receptors in breast cancers}}		{{Estrogen and progesterone receptors in breast cancers}}

Mikael Häggström:

2022-12-02T23:46:54Z

← Older revision		Revision as of 19:46, 2 December 2022
Line 1:		Line 1:
	{{Top		<noinclude>{{Top
	\|author1=[[User:Mikael Häggström\|Mikael Häggström]]		\|author1=[[User:Mikael Häggström\|Mikael Häggström]]
	\|author2=		\|author2=
	}}		}}</noinclude>
	Invasive lobular carcinoma (ILC):		Invasive lobular carcinoma (ILC):
	==Gross examination==		==Gross examination==
Line 93:		Line 93:
	File:Immunohistochemistry for progesterone in invasive lobular carcinoma, staining 61-70 percent.jpg\|Progesterone recepotor, moderate intensity, 61-70% of nuclei.		File:Immunohistochemistry for progesterone in invasive lobular carcinoma, staining 61-70 percent.jpg\|Progesterone recepotor, moderate intensity, 61-70% of nuclei.
	</gallery>		</gallery>
	===Neoadjuvant cases===		<noinclude>===Neoadjuvant cases===
	{{Microscopic evaluation of neoadjuvant invasive cancer}}		{{Microscopic evaluation of neoadjuvant invasive cancer}}
	{{Evaluation of tumors}}		{{Evaluation of tumors}}
	{{Reporting of invasive breast cancer}}		{{Reporting of invasive breast cancer}}
	{{Bottom}}		{{Bottom}}</noinclude>

Mikael Häggström: /* Mitotic count */ Templated

2022-11-06T22:29:06Z

Mitotic count: Templated

← Older revision		Revision as of 18:29, 6 November 2022
Line 79:		Line 79:

	==== Mitotic count ====		==== Mitotic count ====
	~~[[File:Mitosis appearances~~ in breast cancer~~.jpg\|thumb\|Mitosis appearances in breast cancer]]~~		{{Mitotic count in invasive breast cancer}}
	~~Mitotic figures are counted only at the periphery of the tumor, and counting should begin in the most mitotically active areas.~~
	* 1 point: Between 0-5 and 0-11 mitotic counts per 10 high-power fields (HPFs), depending on type of microscope used.<ref name=HPF group=note>Mitotic count:
	* 1 point: 0-9 mitotic counts per 10 fields under X25 objective using the Leitz Ortholux microscope, 0-5 mitotic counts per 10 fields under X40 objective using the Nikon Labophot microscope, or 0-11 mitotic counts per 10 fields under X40 objective using the Leitz Daiplan microscope
	* 2 points: 10-19 mitotic counts per 10 fields under X25 objective using the Leitz Ortholux microscope, 6-10 mitotic counts per 10 fields under X40 objective using the Nikon Labophot microscope, or 12-22 mitotic counts per 10 fields under X40 objective using the Leitz Daiplan microscope
	* 3 points: Over 19 mitotic counts per 10 fields under X25 objective using the Leitz Ortholux microscope, over 10 mitotic counts per 10 fields under X40 objective using the Nikon Labophot microscope, or over 22 mitotic counts per 10 fields under X40 objective using the Leitz Daiplan microscope</ref>
	* 2 points: Between 6-10 and 12-22 mitotic counts per 10 HPFs.<ref name=HPF group=note/>
	* 3 points: Over 10 to 22 mitotic counts per 10 HPFs.<ref name=HPF group=note/>

	==== Overall grade ====		==== Overall grade ====

Mikael Häggström: Note

2022-06-19T20:50:47Z

Note

← Older revision		Revision as of 16:50, 19 June 2022
Line 81:		Line 81:
	[[File:Mitosis appearances in breast cancer.jpg\|thumb\|Mitosis appearances in breast cancer]]		[[File:Mitosis appearances in breast cancer.jpg\|thumb\|Mitosis appearances in breast cancer]]
	Mitotic figures are counted only at the periphery of the tumor, and counting should begin in the most mitotically active areas.		Mitotic figures are counted only at the periphery of the tumor, and counting should begin in the most mitotically active areas.
	* 1 point: Between 0-5 and 0-11 mitotic counts per 10 high-power fields (HPFs), depending on type of microscope used.<ref name=HPF group=~~notes~~>Mitotic count:		* 1 point: Between 0-5 and 0-11 mitotic counts per 10 high-power fields (HPFs), depending on type of microscope used.<ref name=HPF group=note>Mitotic count:
	* 1 point: 0-9 mitotic counts per 10 fields under X25 objective using the Leitz Ortholux microscope, 0-5 mitotic counts per 10 fields under X40 objective using the Nikon Labophot microscope, or 0-11 mitotic counts per 10 fields under X40 objective using the Leitz Daiplan microscope		* 1 point: 0-9 mitotic counts per 10 fields under X25 objective using the Leitz Ortholux microscope, 0-5 mitotic counts per 10 fields under X40 objective using the Nikon Labophot microscope, or 0-11 mitotic counts per 10 fields under X40 objective using the Leitz Daiplan microscope
	* 2 points: 10-19 mitotic counts per 10 fields under X25 objective using the Leitz Ortholux microscope, 6-10 mitotic counts per 10 fields under X40 objective using the Nikon Labophot microscope, or 12-22 mitotic counts per 10 fields under X40 objective using the Leitz Daiplan microscope		* 2 points: 10-19 mitotic counts per 10 fields under X25 objective using the Leitz Ortholux microscope, 6-10 mitotic counts per 10 fields under X40 objective using the Nikon Labophot microscope, or 12-22 mitotic counts per 10 fields under X40 objective using the Leitz Daiplan microscope
	* 3 points: Over 19 mitotic counts per 10 fields under X25 objective using the Leitz Ortholux microscope, over 10 mitotic counts per 10 fields under X40 objective using the Nikon Labophot microscope, or over 22 mitotic counts per 10 fields under X40 objective using the Leitz Daiplan microscope</ref>		* 3 points: Over 19 mitotic counts per 10 fields under X25 objective using the Leitz Ortholux microscope, over 10 mitotic counts per 10 fields under X40 objective using the Nikon Labophot microscope, or over 22 mitotic counts per 10 fields under X40 objective using the Leitz Daiplan microscope</ref>
	* 2 points: Between 6-10 and 12-22 mitotic counts per 10 HPFs.<ref name=HPF group=~~notes~~/>		* 2 points: Between 6-10 and 12-22 mitotic counts per 10 HPFs.<ref name=HPF group=note/>
	* 3 points: Over 10 to 22 mitotic counts per 10 HPFs.<ref name=HPF group=~~notes~~/>		* 3 points: Over 10 to 22 mitotic counts per 10 HPFs.<ref name=HPF group=note/>

	==== Overall grade ====		==== Overall grade ====

Mikael Häggström: +ER and PR

2022-06-10T00:16:07Z

+ER and PR

← Older revision		Revision as of 20:16, 9 June 2022
Line 94:		Line 94:
	* 8-9 '''Grade 3''' tumor ('''poorly differentiated'''). Worst prognosis.		* 8-9 '''Grade 3''' tumor ('''poorly differentiated'''). Worst prognosis.

	{{Immunohistochemistry evaluation of breast cancer}}		{{Immunohistochemistry evaluation of invasive breast cancer}}
	*'''Estrogen and progesterone~~''' receptor positivity~~		====Estrogen and progesterone receptors====
			{{Estrogen and progesterone receptors in breast cancers}}
	<gallery>		<gallery>
	File:Immunohistochemistry for progesterone in invasive lobular carcinoma, staining 61-70 percent.jpg\|Progesterone recepotor, moderate intensity, 61-70% of nuclei.		File:Immunohistochemistry for progesterone in invasive lobular carcinoma, staining 61-70 percent.jpg\|Progesterone recepotor, moderate intensity, 61-70% of nuclei.

Mikael Häggström: small change

2021-12-04T19:23:05Z

small change

← Older revision		Revision as of 15:23, 4 December 2021
Line 3:		Line 3:
	\|author2=		\|author2=
	}}		}}
	Invasive lobular carcinoma (ILC):		Invasive lobular carcinoma (ILC):
	==Gross examination==		==Gross examination==
	As per:		As per:

Mikael Häggström: small change

2021-12-04T19:21:24Z

small change

← Older revision		Revision as of 15:21, 4 December 2021
Line 3:		Line 3:
	\|author2=		\|author2=
	}}		}}
	Invasive lobular carcinoma (ILC):		Invasive lobular carcinoma (ILC):
	==Gross examination==		==Gross examination==
	As per:		As per:

Mikael Häggström: small change

2021-12-04T19:20:14Z

small change

← Older revision		Revision as of 15:20, 4 December 2021
Line 3:		Line 3:
	\|author2=		\|author2=
	}}		}}
	Invasive lobular carcinoma (ILC):		Invasive lobular carcinoma (ILC):
	==Gross examination==		==Gross examination==
	As per:		As per: